论文部分内容阅读
目的观察甲泼尼龙对哮喘患者气道纤维化转化因子的影响,为临床治疗提供参考。方法选择急性哮喘患者34例作为观察组,选择同期行支气管镜活检的非哮喘患者34例作为对照组,观察组采用沙丁胺醇吸入联合口服甲泼尼龙片治疗,比较2组治疗前后气管组织纤维化转化因子-β(TGF-β)水平,统计观察组患者治疗3 d后临床症状及体征缓解情况,分析甲泼尼龙对哮喘患者气道组织TGF-β的影响。结果观察组治疗3 d后,临床症状缓解率为94.1%(32/34),临床体征缓解率为91.2%(31/34)。观察组治疗前TGF-β明显高于对照组(P<0.01);观察组治疗2周后TGF-β与治疗前比较差异无统计学意义(P>0.05)。结论甲泼尼龙对哮喘患者TGF-β无影响,说明甲泼尼龙治疗急性哮喘并不能从根本上降低气道纤维转化,临床应增加针对性更强的靶向治疗方案。
Objective To observe the effect of methylprednisolone on airway fibrosis in asthmatic patients and provide reference for clinical treatment. Methods Thirty-four patients with acute asthma were selected as the observation group. 34 non-asthmatic patients undergoing bronchoscopic biopsy in the same period were selected as the control group. Salbutamol inhalation and oral methylprednisolone tablets were used in the observation group. The tracheal tissue fibrosis was compared between the two groups The level of TGF-β was observed. The clinical symptoms and symptom relief were observed 3 days after treatment in the observation group. The effect of methylprednisolone on TGF-β in airway of asthmatic patients was analyzed. Results After 3 days of treatment, the clinical symptom relief rate was 94.1% (32/34) and the clinical symptom relief rate was 91.2% (31/34). The TGF-β in the observation group before treatment was significantly higher than that in the control group (P <0.01). There was no significant difference in TGF-β between the two groups after treatment for 2 weeks (P> 0.05). Conclusion Methylprednisolone has no effect on TGF-β in asthmatic patients, indicating that methylprednisolone treatment of acute asthma can not fundamentally reduce airway fibrosis, and more targeted targeted therapies should be added clinically.